Edgewise therapeutics, inc.EWTX.US Overview
US StockHealthcare
(No presentation for EWTX)
EWTX Overall Performance
EWTX AI Analysis & Strategy
EWTX Recent Performance
4.35%
Edgewise therapeutics, inc.
0.81%
Avg of Sector
-1.14%
S&P500
EWTX PowerScanner
EWTX Key Information
EWTX Valuation Metrics
EWTX Earnings Table
EWTX Profile
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.